1. Market Research
  2. > Pharmaceutical Market Trends
  3. > IMS Pharmaceutical Pricing & Reimbursement Concise Guide: Spain

The Pharmaceutical Pricing & Reimbursement Concise Guides are established as the definitive reference and training text for P&R professionals around the world, drawing on the long-standing expertise of the IMS pricing and reimbursement specialists to provide industry players and decision makers with a thorough understanding of the rules and regulations governing P&R in international markets. This report covers key developments in P&R, market access, cost containment, trade margins and healthcare issues.

Table Of Contents

IMS Pharmaceutical Pricing and Reimbursement Concise Guide: Spain
SPAIN 1
HEALTHCARE SYSTEM 1
Facts and Figures 1
Market Indicators 2
Provision and Funding 4
National Health Service 4
Decentralisation 4
Funding 5
Provision 5
PRICING 5
Prescription Drugs 5
Reimbursed Drugs 5
Non-reimbursed Drugs 7
Mandatory Distribution Chain Discounts 8
Generic Drugs 8
Hospital Drugs 9
Risk-sharing and Expenditure Agreements 9
Reference Prices 9
Regional Centralised Purchasing 10
National Centralised Purchasing 10
OTC Drugs 11
REIMBURSEMENT 11
Admission to Reimbursement 11
Reimbursement Decisions 11
Negative List 12
Local Listing 12
Reimbursement Categories 13
Reimbursement Prices 13
Reference Prices 13
Cheapest Price/‘Actual' Cheapest Price 15
Selective Reimbursement Prices 16
Andalucía Retail Sector Tenders 16
Hospital Reimbursement 17
Formularies 17
Funding 17
Out-patient Dispensing 18
Changes in Reimbursement Status 18
Changes in Reimbursement Prices 19
Price Revisions 19
Price Increases 19
Price Decreases 19
Mandatory Distribution Chain Discounts 19
PHARMACOECONOMICS 20
Pharmacoeconomic Requirements 20
Spain, Pharmaceutical Pricing and Reimbursement Concise Guide
v
HTA Developments 20
Draft Royal Decree 21
PRICE BUILD UP 21
Wholesalers 21
Margins 21
Mandatory Discounts 21
Background 22
Retail Pharmacies 22
Margins 22
Mandatory Discounts 22
Other Discounts 22
Pharmacy Clawbacks 22
Extra Financial Support 23
Pharmacy Provision and Regulation 24
E-pharmacy 24
Unit Dose Dispensing 25
Dispensing Doctors 25
Sales Tax 25
COST CONTAINMENT 25
Industry Paybacks 25
Risk-sharing/Maximum Expenditure Agreements 26
Industry Pact 26
Promotional Costs 26
Patient Co-payments 27
Pharmaceuticals 27
Healthcare 28
Prescribing Controls 28
National Controls 28
Regional Drug Evaluation Committees 29
Regional Prescribing Targets 29
Regional Electronic Prescribing Systems 30
Regional Visas 30
Regional Listing 30
Generics 31
INN Prescribing 31
Dispensing Decisions 31
Generic Substitution 31
Promotion of Generics 31
Rx-to-OTC Switches 31
Parallel Trade 32
Drug Tracing 33
FUTURE DEVELOPMENTS 33
Outlook 33
Royal Decree on Pricing and Reimbursement 33
Government Pacts with Industry 36
National vs Regional Control 37
NAMES and ADDRESSES 38

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.